Optimal Inhalation Therapy for Chronic Obstructive Pulmonary Disease(COPD) Patients
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to examine whether long-acting muscarinic antagonist
(LAMA) administration at bedtime versus in the morning leads to a reduction in severe acute
exacerbations of chronic obstructive pulmonary disease (AECOPD) among COPD-patients who are
already receiving treatment with LAMAs. The hypothesis is that bedtime administration of
LAMA, as opposed to morning administration, will lead to fewer severe AECOPD exacerbations.
Further, bedtime administration of LAMA will lead to fewer moderate AECOPD´s, fewer cases
where non-invasive ventilation (NIV) is needed and a lower mortality in COPD patients who are
already using LAMAs.